Short and Long-Term Effects of the Exposure of Breast Cancer Cell Lines to Different Ratios of Free or Co-Encapsulated Liposomal Paclitaxel and Doxorubicin

Background: Associating paclitaxel (PTX) to doxorubicin (DXR) is one of the main chemotherapy strategies for breast cancer (BC) management. Protocols currently available consist in administering both drugs on their maximum tolerated dose, not taking into account the possible differences in efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco, Marina Santiago, Roque, Marjorie Coimbra, Oliveira, Mônica Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523953/
https://www.ncbi.nlm.nih.gov/pubmed/30979090
http://dx.doi.org/10.3390/pharmaceutics11040178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523953/
https://www.ncbi.nlm.nih.gov/pubmed/30979090
http://dx.doi.org/10.3390/pharmaceutics11040178

Ejemplares similares